Arogya Aarohan app & other AI-driven tools are being tested for early detection of diseases as part of Rs 300-cr initiative ...

The collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...

“I think some of the new treatments will probably move the needle a little bit more in terms of treating this indication.” Ip MS. Update on the current treatment of diabetic retinopath ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Not available at this time. 1515 Aquarena Springs Drive, Ste. 105, San Marcos ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

The FDA previously agreed that together, these studies could constitute two adequate and well-controlled trials to support a potential New Drug Application ... being evaluated for the treatment of wet ...

Striking a balance between innovation and responsibility is imperative. By prioritizing transparency, adhering to robust ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...